Pharma Giants Beat Sales Expectations Amid Diverging Profit Forecasts

Pharmaceutical giants Merck and Pfizer have raised their full-year sales outlooks after beating quarterly revenue expectations, but divergent profit forecasts suggest a complex landscape.

Merk lifted its 2026 revenue guidance to $66.3 billion-$67.3 billion following a 5% increase in second-quarter sales to $16.61 billion, exceeding the estimated $16.37 billion. However, adjusted earnings per share (EPS) guidance fell to $2.66-$2.76 due to a $2.43-per-share charge tied to its Terns Pharmaceuticals acquisition.

Pfizer also tightened its revenue range to $60.5 billion-$62.5 billion after sales rose 3% to $15.03 billion, with adjusted EPS of $0.77 compared to the expected $0.68. The contrast in profit forecasts highlights how acquisitions can create an 'optics gap' where revenue trends improve while EPS appears worse due to purchase-accounting charges.

Investors and analysts focus on run-rate profitability, what earnings might look like once one-off charges fade, and guidance versus consensus estimates. Near-term share moves often result from revised analyst models rather than quarter headline revenue beats alone.